Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dawn Atwal

Cardiovascular Disease Laguna Beach, CA Medical Doctor

NPI 1275579278 CMS profile 148217

31852 Coast Hwy Ste 410, Laguna Beach, CA 92651

Open in the dashboard

General payments

$5,912

191 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dawn Atwal of Laguna Beach, CA is reported in the CMS Open Payments database as having received $5,912 across 191 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $686 20
2024 General $1,383 28
2023 General $392 19
2022 General $449 17
2021 General $951 29
2020 General $553 22
2019 General $1,499 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dawn Atwal
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Dawn Atwal were reported at $686. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Dawn Atwal Cardiovascular Disease median Middle half National median
2019 $1,499 $450 $127–$1,392 $163
2020 $553 $242 $77–$751 $114
2021 $951 $335 $101–$1,037 $132
2022 $449 $395 $121–$1,211 $149
2023 $392 $443 $136–$1,283 $160
2024 $1,383 $450 $136–$1,323 $164
2025 $686 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biotronik Inc. $2,051 24 payments
  2. Boston Scientific Corporation $662 16 payments
  3. Janssen Pharmaceuticals, Inc $412 19 payments
  4. Pfizer Inc. $401 21 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $382 13 payments
  6. Novartis Pharmaceuticals Corporation $361 20 payments
  7. E.R. Squibb & Sons, L.L.C. $335 16 payments
  8. AstraZeneca Pharmaceuticals LP $321 15 payments
  9. Amgen Inc. $287 15 payments
  10. Novo Nordisk Inc $168 8 payments
  11. Other $533 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,298 188 payments
  2. Travel and Lodging $565 1 payment
  3. Education $49 2 payments
Products named General payments · program years 2019–2025
  1. Solia $1,044 6 payments
  2. Acticor 7 VR-T DX $799 3 payments
  3. BIOMONITOR Cardiology/Vascular Diseases $730 5 payments
  4. AMVIA EDGE $713 4 payments
  5. Selectra $565 1 payment
  6. BioMonitor Cardiology/Vascular Diseases $505 6 payments
  7. AVVIGO Guidance System $490 10 payments
  8. Rivacor $479 5 payments
  9. Edora $479 5 payments
  10. Acticor $479 5 payments
  11. Other $3,941 183 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

2,415

Median for Cardiology: 2,533

Drug cost

$286,813

Median for Cardiology: $485,213

Branded share of claims

9.7%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 94 $116,166
Xarelto Rivaroxaban Brand 100 $115,645
Entresto Sacubitril/Valsartan Brand 15 $28,006
Metoprolol Succinate Generic 401 $6,203
Rosuvastatin Calcium Generic 298 $4,797
Losartan Potassium Generic 403 $4,513
Amlodipine Besylate Generic 370 $2,378
Atorvastatin Calcium Generic 118 $1,368
Olmesartan Medoxomil Generic 21 $1,038
Amiodarone Hcl Generic 27 $725

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$446,365

Of which drugs: $859

Medicare patients

704

Average age 78

Services billed

7,391

379 women, 325 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Atrial fibrillation 34%
Ischemic heart disease 33%
Chronic kidney disease 31%
Diabetes 28%
Heart failure 24%
Depression 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 40 164 $859

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $59
$59 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $43
$43 — —
Wegovy
  • Novo Nordisk Inc $41
$41 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $32
$32 — —
Ozempic
  • Novo Nordisk Inc $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

191 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record